Vitamin D analogues in colon cancer prevention and care

Current Colorectal Cancer Reports

Volumn 5, Issue 4, 2009, Pages 185-196

  Beildeck, Marcy E ^a   Byers, Stephen W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; ANTINEOPLASTIC AGENT; GEMINI DERIVATIVE; PARICALCITOL; RO 24 5531; RO 25 5317; RO 26 9114; RO 27 2310; SEOCALCITOL; SULINDAC; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; ZK 191784;

ANTINEOPLASTIC ACTIVITY; BODY WEIGHT; CALCIUM BLOOD LEVEL; CANCER PREVENTION; CANCER RESEARCH; CHEMICAL REACTION; COLORECTAL CANCER; DRUG STRUCTURE; DRUG TREATMENT FAILURE; HOMOLOGATION; HUMAN; HYPERCALCEMIA; MEDICAL LITERATURE; MULTIPLE CYCLE TREATMENT; NONHUMAN; REVIEW; SIDE EFFECT;

EID: 79952639594     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-009-0026-5     Document Type: Review

References (57)

1. Thorne J, Campbell MJ: The vitamin D receptor in cancer. Proc Nutr Soc 2008, 67:115-127. (Pubitemid 351543394)
2. Rochel N, Wurtz JM, Mitschler A, et al.: The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 2000, 5:173-179. (Pubitemid 30105446)
3. Cross HS, Bajna E, Bises G, et al.: Vitamin D receptor and cytokeratin expression may be progression indicators in human colon cancer. Anticancer Res 1996, 16:2333-2337. (Pubitemid 26265587)
4. Nemere I, Yoshimoto Y, Norman AW: Calcium-transport in perfused duodena from normal chicks - enhancement within 14 minutes of exposure to 1,25-dihydroxyvitamin-D3. Endocrinology 1984, 115:1476-1483. (Pubitemid 14000314)
5. Saito T, Okamoto R, Haritunians T, et al.: Novel Gemini vitamin D-3 analogs have potent antitumor activity. J Steroid Biochem Mol Biol 2008, 112:151-156.
6. Maehr H, Uskokovic M, Adorini L, et al.: Calcitriol derivatives with two different side chains at C-20III. An epimeric pair of the gemini family with unprecedented antiproliferative effects on tumor cells and renin mRNA expression inhibition. J Steroid Biochem Mol Biol 2007, 103:277-281. (Pubitemid 46401301)
7. Scaglione-Sewell BA, Bissonnette M, Skarosi S, et al.: A vitamin D-3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting Cdk2 and Cdk6: roles of cyclin E, p21(Waf1), and p27(Kip1). Endocrinology 2000, 141:3931-3939.
8. Wali RK, Bissonnette M, Khare S, et al.: 1-Alpha,25-dihydroxy- 16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analog of 1-alpha,25-dihydroxyvitamin d-3, inhibits azoxymethane-induced colonic tumorigenesis. Cancer Res 1995, 55:3050-3054.
9. Wali RK, Stoiber D, Nguyen L, et al.: Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development. Cancer Epidemiol Biomarkers Prev 2002, 11:1316-1321. (Pubitemid 35340366)
10. Tanaka Y, Wu AYS, Ikekawa N, et al.: Inhibition of Ht-29 human colon-cancer growth under the renal capsule of severe combined immunodeficient mice by an analog of 1,25-dihydroxyvitamin D-3, Dd-003. Cancer Res 1994, 54:5148-5153. (Pubitemid 24313492)
11. Huerta S, Irwin RW, Heber D, et al.: 1alpha,25-(OH)(2)- D(3) and its synthetic analogue decrease tumor load in the Apc(min) mouse. Cancer Res 2002, 62:741-746. (Pubitemid 34126949)
12. Otoshi T, Iwata H, Kitano M, et al.: Inhibition of intestinal tumor-development in rat multiorgan carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22-oxa-calcitriol, a synthetic analog of 1-alpha,25-dihydroxyvitamin D-3. Carcinogenesis 1995, 16:2091-2097.
13. Tanaka Y, Bush KK, Eguchi T, et al.: Effects of 1,25- dihydroxyvitamin-D3 and its analogs on butyrate-induced differentiation of HT-29 human colonic-carcinoma cells and on the reversal of the differentiated phenotype. Arch Biochem Biophys 1990, 276:415-423. (Pubitemid 20081973)
14. Takaku H, Miyamoto Y, Asami S, et al.: Synthesis and structure-activity relationships of 16-ene-22-thia-1 alpha,25-dihydroxy-26,27-dimethyl-19- norvitamin D-3 analogs having side chains of different sizes. Bioorg Med Chem 2008, 16:1796-1815. (Pubitemid 351226586)
15. Gaschott T, Steinhilber D, Stein J: ZK 156718, a novel low calcemic vitamin D analog with strong antiproliferative and differentiation-inducing effects on Caco-2 cells. Gastroenterology 2002, 122:A372.
16. Hansen CM, Maenpaa PH: EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells. Biochem Pharmacol 1997, 54:1173-1179.
17. Akhter J, Goerdel M, Morris DL: Vitamin D-3 analogue (EB 1089) inhibits in vitro cellular proliferation of human colon cancer cells. Br J Surg 1996, 83:229-230. (Pubitemid 26050150)
18. Oh YS, Kim EJ, Schaffer BS, et al.: Synthetic low-calcaemic vitamin D-3 analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol Cell Endocrinol 2001, 183:141-149. (Pubitemid 32938520)
19. Diaz GD, Paraskeva C, Thomas MG, et al.: Apoptosis is induced by the active metabolite of vitamin D-3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 2000, 60:2304-2312. (Pubitemid 30225198)
20. Akhter J, Chen XH, Bowrey P, et al.: Vitamin D-3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis Colon Rectum 1997, 40:317-321. (Pubitemid 27120140)
21. Gulliford T, English J, Colston KW, et al.: A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998, 78:6-13. (Pubitemid 28276762)
22. Cross HS, Farsoudi KH, Peterlik M: Growth inhibition of human colon adenocarcinoma-derived Caco-2 cells by 1,25- dihydroxyvitamin D3 and two synthetic analogs: relation to in vitro hypercalcemic potential. Naunyn Schmiedebergs Arch Pharmacol 1993, 347:105-110. (Pubitemid 23036943)
23. Bischof MG, Redlich K, Schiller C, et al.: Growth inhibitory effects on human colon adenocarcinoma-derived Caco-2 cells and calcemic potential of 1 alpha,25-dihydroxyvitamin D3 analogs: structure-function relationships. J Pharmacol Exp Ther 1995, 275:1254-1260. (Pubitemid 26130637)
24. Vandewalle B, Wattez N, Lefebvre J: Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Cancer Lett 1995, 97:99-106.
25. Shabahang M, Buras RR, Davoodi F, et al.: Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3. Cancer Res 1994, 54:4057-4064.
26. Tong WM, Bises G, Sheinin Y, et al.: Establishment of primary cultures from human colonic tissue during tumor progression: vitamin-D responses and vitamin-D-receptor expression. Int J Cancer 1998, 75:467-472. (Pubitemid 28100052)
27. Evans SRT, Soldatenkov V, Shchepotin EB, et al.: Novel 19-nor-hexafluoride vitamin D-3 analog (Ro 25-6760) inhibits human colon cancer in vitro via apoptosis. Int J Oncol 1999, 14:979-985.
28. Thomas MG, Tebbutt S, Williamson RC: Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut 1992, 33:1660-1663.
29. Seow-Choen F, Vijayan V, Keng V: Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis. Br J Surg 1996, 83:1763-1766. (Pubitemid 26421882)
30. Evans SR, Schwartz AM, Shchepotin EI, et al.: Growth inhibitory effects of 1,25-dihydroxyvitamin D3 and its synthetic analogue, 1alpha,25-dihydroxy-16- ene-23yne- 26,27-hexafluoro-19-nor-cholecalciferol (Ro 25-6760), on a human colon cancer xenograft. Clin Cancer Res 1998, 4:2869-2876. (Pubitemid 28523517)
31. Evans SR, Shchepotin EI, Young H, et al.: 1,25-Dihydroxyvitamin D3 synthetic analogs inhibit spontaneous metastases in a 1,2-dimethylhydrazine- induced colon carcinogenesis model. Int J Oncol 2000, 16:1249-1254.
32. Strauch UG, Obermeier F, Grunwald N, et al.: Calcitriol analog ZK191784 ameliorates acute and chronic dextran sodium sulfate-induced colitis by modulation of intestinal dendritic cell numbers and phenotype. World J Gastroenterol 2007, 13:6529-6537.
33. Fichera A, Little N, Dougherty U, et al.: A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. J Surg Res 2007, 142:239-245. This is one of four articles examining the benefits of vitamin D analogues against colitis, a human risk factor for colorectal cancer. It addresses not only colitis as a risk factor, but also regulation of β-catenin-regulated targets by vitamin D analogues.
34. Aparna R, Subhashini J, Roy KR, et al.: Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene- 23-yne-vitamin D3, a less calcemic vitamin D analog. J Cell Biochem 2008, 104:1832-1842.
35. Zierold C, Mings JA, DeLuca HF: 19nor-1,25-dihydroxyvitamin D2 specifically induces CYP3A9 in rat intestine more strongly than 1,25-dihydroxyvitamin D3 in vivo and in vitro. Mol Pharmacol 2006, 69:1740-1747. This article demonstrates the ability of vitamin D analogues bound to VDR to identify unique targets in the gastrointestinal tract, which may lead to the identification of future VDR modulators.
36. Kumagai T, O'Kelly J, Said JW, Koeffler HP: Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst 2003, 95:896-905. (Pubitemid 36833881)
37. Levy Y, Knutson JC, Bishop C, Shany S: The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines. Anticancer Res 1998, 18:1769-1775. (Pubitemid 28342591)
38. Tangpricha V, Spina C, Yao M, et al.: Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J Nutr 2005, 135:2350-2354. (Pubitemid 41429589)
39. Iseki K, Tatsuta M, Uehara H, et al.: Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 1999, 81:730-733. (Pubitemid 29214382)
40. Kawaura A, Tanida N, Nishikawa M, et al.: Inhibitory effect of 1alpha-hydroxyvitamin D3 on N-methyl-N′-nitro- N-nitrosoguanidine-induced gastrointestinal carcinogenesis in Wistar rats. Cancer Lett 1998, 122:227-230. (Pubitemid 28058640)
41. Kikuchi H, Murakami S, Suzuki S, et al.: Chemopreventive effect of a vitamin D(3) analog, alfacalcidol, on colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Drugs 2007, 18:1183-1187. (Pubitemid 47480743)
42. Murillo G, Mehta RG: Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5. J Steroid Biochem Mol Biol 2005, 97:129-136. (Pubitemid 41546222)
43. Iseki K, Kobayashi Y: Fluorinated vitamin D3 analog with in vivo anticancer activity. Biomed Front Fluorine Chem 1996, 639:214-227.
44. Salim EI, Wanibuchi H, Taniyama T, et al.: Inhibition of development of N,N′-dimethylhydrazine-induced rat colonic aberrant crypt foci by pre, post and simultaneous treatments with 24R,25-dihydroxyvitamin D3. Jpn J Cancer Res 1997, 88:1052-1062. (Pubitemid 28021967)
45. Taniyama T, Wanibuchi H, Salim EI, et al.: Chemopreventive effect of 24R,25-dihydroxyvitamin D3 in N,N′-dimethylhydrazine-induced rat colon carcinogenesis. Carcinogenesis 2000, 21:173-178. (Pubitemid 30098699)
46. Eelen G, Valle N, Sato Y, et al.: Superagonistic fluorinated vitamin D3 analogs stabilize helix 12 of the vitamin D receptor. Chem Biol 2008, 59:1029-1034. This article describes subtle differences in the docking of vitamin D analogues compared with cognate ligand. It also looks at the ability of these analogues to affect β-catenin activity.
47. Hofer H, Ho GM, Peterlik M, et al.: Biological effects of 1alpha-hydroxy- and 1beta-(hydroxymethyl) vitamin D compounds relevant for potential colorectal cancer therapy. J Pharmacol Exp Ther 1999, 291:450-455. (Pubitemid 29503511)
48. Peleg S, Ismail A, Uskokovic MR, Avnur Z: Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem 2003, 88:267-273. (Pubitemid 36119897)
49. Norman AW, Bouillon R, Farach-Carson MC, et al.: Demonstration that 1 beta,25-dihydroxyvitamin D3 is an antagonist of the nongenomic but not genomic biological responses and biological profile of the three A-ring diastereomers of 1 alpha,25-dihydroxyvitamin D3. J Biol Chem 1993, 268:20022-20030. (Pubitemid 23278897)
50. Herdick M, Bury Y, Quack M, et al.: Response element and coactivator-mediated conformational change of the vitamin D(3) receptor permits sensitive interaction with agonists. Mol Pharmacol 2000, 57:1206-1217. (Pubitemid 30354393)
51. Carlberg C: Molecular basis of the selective activity of vitamin D analogues. J Cell Biochem 2003, 88:274-281.
52. Shah S, Islam MN, Dakshanamurthy S, et al.: The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell 2006, 21:799-809. This article describes the simultaneous inability of VDR antagonists to recruit classical coactivators and their ability to recruit other coactivators, such as β-catenin. This plays a major role in the context of colorectal cancer because most of them are the direct result of abundant active β-catenin. It supports these analogues in a selective VDR modulator role.
53. Sicinska W, Rotkiewicz P: Structural changes of vitamin D receptor induced by 20-epi-1alpha,25-(OH)(2)D3: an insight from a computational analysis. J Steroid Biochem Mol Biol 2009, 113:253-258. This article describes a novel way to predict analogue docking to the VDR via computational analysis. This method may shed light on VDR conformations previously undetectable by our current method of x-ray crystallography.
54. Beer TM, Munar M, Henner WD: A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001, 91:2431-2439. (Pubitemid 32552832)
55. Muindi JR, Peng YB, Potter DM, et al.: Pharmacokinetics of high-dose oral calcitriol: results from a phase I trial of calcitriol and paclitaxel. Clin Pharmacol Ther 2002, 72:648-659. (Pubitemid 36021004)
56. Baroni E, Camisa B, D'Ambrosio D: Inter-species differences in sensitivity to the calcemic activity of the novel 1,25-dihydroxyvitamin D3 analog BXL746. Regul Toxicol Pharmacol 2008, 52:332-341.
57. Quack M, Carlberg C: Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs. Mol Pharmacol 1999, 55:1077-1087. (Pubitemid 29252375)